PrEP does not weaken your immune system. Studies comparing people taking PrEP to those on placebo have found no meaningful differences in immune cell counts, immune cell activity, or markers of inflammation. The concern makes sense on the surface, since PrEP uses antiretroviral drugs originally developed to treat HIV, but the way these medications work in a healthy body leaves your immune defenses intact.
How PrEP Works Without Affecting Immunity
PrEP protects against HIV through direct antiviral activity, not by changing how your immune system functions. The drugs in PrEP block an enzyme HIV needs to copy itself inside your cells. If the virus enters your body during exposure, PrEP stops it from replicating before it can establish an infection. Your immune cells themselves are not targeted or suppressed in this process.
This is different from immunosuppressive medications (like those used after organ transplants or for autoimmune conditions), which deliberately dial down immune activity. PrEP does nothing of the sort. It sits quietly in your tissues and only becomes relevant when HIV shows up.
What the Immune Cell Data Shows
Researchers have directly measured immune cell populations in people taking PrEP versus placebo, and the results are remarkably similar across the board. In one study published in The Journal of Infectious Diseases, the percentage of CD4+ T cells (the key immune cells HIV targets) was 62.3% in PrEP users and 61.0% in placebo recipients. The rate of chronic immune activation, which would signal the immune system is under stress, was 1.6% versus 1.7%. Neither difference was statistically significant.
The study also looked at different types of immune memory cells, which are critical for fighting infections you’ve encountered before. Naive cells, central memory cells, and effector memory cells were all present in nearly identical proportions in both groups. The same held true for CD8+ T cells, which are responsible for killing virus-infected cells. Overall response rates to immune challenges were statistically indistinguishable between PrEP and placebo groups.
No Signs of Increased Inflammation
Beyond immune cell counts, researchers have also checked whether PrEP triggers low-grade inflammation, the kind that can quietly stress the body over time. A study measuring C-reactive protein (a general inflammation marker) and IL-6 (a signaling molecule involved in immune responses) found no association between PrEP use and elevated levels of either marker. This held true for both current and lifetime PrEP use. The CDC’s own clinical guidance states that PrEP has not caused serious short- or medium-term safety concerns.
Why Early Side Effects Feel Concerning
Some people starting PrEP experience nausea, diarrhea, headache, fatigue, or stomach pain in the first few weeks. It’s easy to interpret these symptoms as a sign that something is going wrong with your body’s defenses, especially when you’re already wondering about immune effects. But these are start-up side effects caused by your body adjusting to the medication, not evidence of immune suppression. They typically fade on their own and are not serious.
Feeling run down or having an upset stomach can mimic what you might associate with being immunocompromised, but the underlying cause is completely different. A weakened immune system shows up as unusual infections, slow wound healing, or recurring illness. PrEP start-up symptoms are gastrointestinal and resolve within weeks.
What PrEP Can Affect: Kidneys and Bones
While PrEP doesn’t touch your immune system, it can have mild effects on kidney function and bone mineral density, particularly the older formulation (Truvada, which contains tenofovir disoproxil fumarate). These effects are generally small and reversible after stopping the medication, but they’re the reason routine monitoring exists.
The CDC recommends kidney function testing every six months while on PrEP. The World Health Organization recommends quarterly testing for the first year, then annually. People over 45, those with high blood pressure, or those who weigh less than 55 kg may benefit from more frequent checks.
The newer formulation (Descovy, which uses tenofovir alafenamide) was developed partly to address these concerns. Clinical trial data showed improved kidney function markers and better bone mineral density compared to Truvada. However, the newer version comes with its own trade-offs: participants showed higher cholesterol levels and more weight gain. In one retrospective study, the proportion of people with elevated lipids increased from 30% to 50% after switching from the older to the newer formulation.
Long-Term Use and Immune Health
PrEP has been studied in clinical trials since the iPrEx study, which specifically tracked immune responses and CD4 counts in participants over time. The consistent finding across trials is that long-term PrEP use does not erode immune function. Your body continues producing immune cells at normal rates, responding to infections normally, and maintaining the same balance of immune cell types as someone not taking the medication.
This makes biological sense. PrEP’s active ingredients interfere with a specific step in HIV’s replication cycle. They don’t interact with the machinery your immune cells use to divide, mature, or respond to threats. Your body’s ability to fight off a cold, respond to a vaccine, or heal a wound remains unchanged.